Floatz logo

Selinexor

Acinar Cell Adenocarcinoma of the Pancreas

Mohammed Najeeb Al HallakSmall moleculePhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Acinar Cell Adenocarcinoma of the Pancreas cohort.

Asset / SponsorPhaseRating
Eloxatin
Yale University
Phase 2BBB
FLUOROURACILUM
Yale University
Phase 2BBB
Irinotecan
Artios Pharma Ltd
Phase 2BB
Metformin
Case Comprehensive Cancer Center
Phase 2BB
Wild-Type Reovirus
National Cancer Institute (NCI)
Phase 2B

View all 34 →

Same molecule, other indications

Selinexor is also rated in:

diffuse large B-cell lymphomaDormant
BBB
Indicative ·
72 / 100
View asset →
mantle cell lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
relapsed/refractory diffuse large B-cell lymphomaDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →